Regulation of mitochondrial dysfunction by estrogens and estrogen receptors in Alzheimer's disease: A focused review.
Alzheimer's disease
estrogen receptors
estrogens
glucose metabolism
mitochondrial bioenergetics
mitochondrial dynamics
mitochondrial estrogen receptor
mitochondrial function
sex differences
Journal
Basic & clinical pharmacology & toxicology
ISSN: 1742-7843
Titre abrégé: Basic Clin Pharmacol Toxicol
Pays: England
ID NLM: 101208422
Informations de publication
Date de publication:
27 May 2024
27 May 2024
Historique:
revised:
02
05
2024
received:
01
03
2024
accepted:
07
05
2024
medline:
27
5
2024
pubmed:
27
5
2024
entrez:
27
5
2024
Statut:
aheadofprint
Résumé
Alzheimer's disease (AD) is a neurodegenerative disorder that primarily manifests itself by progressive memory loss and cognitive decline, thus significantly affecting memory functions and quality of life. In this review, we proceed from the understanding that the canonical amyloid-β hypothesis, while significant, has faced setbacks, highlighting the need to adopt a broader perspective considering the intricate interplay of diverse pathological pathways for effective AD treatments. Sex differences in AD offer valuable insights into a better understanding of its pathophysiology. Fluctuation of the levels of ovarian sex hormones during perimenopause is associated with changes in glucose metabolism, as a possible window of opportunity to further understand the roles of sex steroid hormones and their associated receptors in the pathophysiology of AD. We review these dimensions, emphasizing the potential of estrogen receptors (ERs) to reveal mitochondrial functions in the search for further research and therapeutic strategies for AD pharmacotherapy. Understanding and addressing the intricate interactions of mitochondrial dysfunction and ERs potentially pave the way for more effective approaches to AD therapy.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Brain & Behavior Research Foundation
Organisme : Molly Lou Foundation
ID : 31803
Informations de copyright
© 2024 The Author(s). Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
Références
Shi J, Sabbagh MN, Vellas B. Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions. BMJ. 2020;371. doi:10.1136/BMJ.M3684
Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer's disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2020;16(11):1553‐1560. doi:10.1016/J.JALZ.2019.09.075
Aanerud J, Borghammer P, Rodell A, Jónsdottir KY, Gjedde A. Sex differences of human cortical blood flow and energy metabolism. J Cereb Blood Flow Metab. 2017;37(7):2433‐2440. doi:10.1177/0271678X16668536
Aggarwal NT, Mielke MM. Sex differences in Alzheimer's disease. Neurol Clin. 2023;41(2):343‐358. doi:10.1016/J.NCL.2023.01.001
Ferretti MT, Lulita MF, Cavedo E, et al. Sex differences in Alzheimer disease—the gateway to precision medicine. Nat Rev Neurol. 2018;14(8):457‐469. doi:10.1038/s41582‐018‐0032‐9
Brinton RD, Yao J, Yin F, Mack WJ, Cadenas E. Perimenopause as a neurological transition state. Nat Rev Endocrinol. 2015;11(7):393‐405. doi:10.1038/nrendo.2015.82
Ashleigh T, Swerdlow RH, Beal MF. The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis. Alzheimers Dement. 2023;19(1):333‐342. doi:10.1002/ALZ.12683
Neha PS. Emerging therapeutics agents and recent advances in drug repurposing for Alzheimer's disease. Ageing Res Rev. 2023;85:101815. doi:10.1016/J.ARR.2022.101815
Hampel H, Mesulam MM, Cuello AC, et al. Revisiting the cholinergic hypothesis in Alzheimer's disease: emerging evidence from translational and clinical research. J Prev Alzheimers Dis. 2018;6(1):2‐15. doi:10.14283/JPAD.2018.43
Mietelska‐Porowska A, Wasik U, Goras M, Filipek A, Niewiadomska G. Tau protein modifications and interactions: their role in function and dysfunction. Int J Mol Sci. 2014;15(3):4671‐4713. doi:10.3390/IJMS15034671
Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018;4:575‐590. doi:10.1016/J.TRCI.2018.06.014
Chen CH, Zhou W, Liu S, et al. Increased NF‐κB signalling up‐regulates BACE1 expression and its therapeutic potential in Alzheimer's disease. Int J Neuropsychopharmacol. 2012;15(1):77‐90. doi:10.1017/S1461145711000149
Cascella R, Cecchi C. Calcium dyshomeostasis in Alzheimer's disease pathogenesis. Int J Mol. 2021;22(9):4914. doi:10.3390/IJMS22094914
Zhao R, Jiang S, Zhang L, Yu Z. Mitochondrial electron transport chain, ROS generation and uncoupling. Int J Mol Med. 2019;44(1):3‐15.
Giorgi C, Agnoletto C, Bononi A, et al. Mitochondrial calcium homeostasis as potential target for mitochondrial medicine. Mitochondrion. 2012;12(1):77‐85.
Xiong S, Mu T, Wang G, Jiang X. Mitochondria‐mediated apoptosis in mammals. Protein Cell. 2014;5(10):737‐749.
Nickel A, Kohlhaas M, Maack C. Mitochondrial reactive oxygen species production and elimination. J Mol Cell Cardiol. 2014;73:26‐33.
Bhatti JS, Bhatti GK, Reddy PH. Mitochondrial dysfunction and oxidative stress in metabolic disorders—a step towards mitochondria based therapeutic strategies. Biochim Biophys Acta (BBA)‐Mol Basis Dis. 2017;1863(5):1066‐1077.
Chistiakov DA, Shkurat TP, Melnichenko AA, Grechko AV, Orekhov AN. The role of mitochondrial dysfunction in cardiovascular disease: a brief review. Ann Med. 2018;50(2):121‐127.
Hsu CC, Tseng LM, Lee HC. Role of mitochondrial dysfunction in cancer progression. Exp Biol Med. 2016;241(12):1281‐1295.
Akbar M, Essa MM, Daradkeh G, et al. Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stress. Brain Res. 2016;1637:34‐55.
Moreira PI, Carvalho C, Zhu X, Smith MA, Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta (BBA)‐Mol Basis Dis. 2010;1802(1):2‐10.
Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener. 2020;15:1‐22.
Swerdlow RH, Burns JM, Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (BBA)‐Mol Basis Dis. 2014;1842(8):1219‐1231.
Bonda DJ, Wang X, Perry G, Smith MA, Zhu X. Mitochondrial dynamics in Alzheimer's disease: opportunities for future treatment strategies. Drugs Aging. 2010;27:181‐192.
Baloyannis SJ, Mavroudis I, Baloyannis IS, Costa VG. Mammillary bodies in Alzheimer's disease: a Golgi and electron microscope study. Am J Alzheimers Dis Other Demen. 2016;31(3):247‐256.
Baloyannis SJ, Costa V, Michmizos D. Mitochondrial alterations Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2004;19(2):89‐93.
Baloyannis SJ, Mavroudis I, Mitilineos D, Baloyannis IS, Costa VG. The hypothalamus in Alzheimer's disease: a Golgi and electron microscope study. Am J Alzheimers Dis Other Demen. 2015;30(5):478‐487.
Wang X, Su BO, Fujioka H, Zhu X. Dynamin‐like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol. 2008;173(2):470‐482.
Chan DC. Fusion and fission: interlinked processes critical for mitochondrial health. Annu Rev Genet. 2012;46:265‐287.
Reiss AB, Ahmed S, Dayaramani C, et al. The role of mitochondrial dysfunction in Alzheimer's disease: a potential pathway to treatment. Exp Gerontol. 2022;164:111828.
Manczak M, Calkins MJ, Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Hum Mol Genet. 2011;20(13):2495‐2509.
Paidi RK, Nthenge‐Ngumbau DN, Singh R, Kankanala T, Mehta H, Mohanakumar KP. Mitochondrial deficits accompany cognitive decline following single bilateral intracerebroventricular streptozotocin. Curr Alzheimer Res. 2015;12(8):785‐795.
Joshi AU, Saw NL, Shamloo M, Mochly‐Rosen D. Drp1/Fis1 interaction mediates mitochondrial dysfunction, bioenergetic failure and cognitive decline in Alzheimer's disease. Oncotarget. 2018;9(5):6128.
Baek SH, Park SJ, Jeong JI, et al. Inhibition of Drp1 ameliorates synaptic depression, Aβ deposition, and cognitive impairment in an Alzheimer's disease model. J Neurosci. 2017;37(20):5099‐5110.
Gustafson MA, Sullivan ED, Copeland WC. Consequences of compromised mitochondrial genome integrity. DNA Repair (Amst). 2020;93:102916.
Maruszak A, Żekanowski C. Mitochondrial dysfunction and Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(2):320‐330.
Kong M, Guo L, Xu W, et al. Aging‐associated accumulation of mitochondrial DNA mutations in tumor origin. Life Med. 2022;1(2):149‐167.
Wang J, Xiong S, Xie C, Markesbery WR, Lovell MA. Increased oxidative damage in nuclear and mitochondrial DNA in Alzheimer's disease. J Neurochem. 2005;93(4):953‐962.
Chang SW, Zhang D, Chung HD, Zassenhaus HP. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. Biochem Biophys Res Commun. 2000;273(1):203‐208.
Elson JL, Herrnstadt C, Preston G, et al. Does the mitochondrial genome play a role in the etiology of Alzheimer's disease? Hum Genet. 2006;119:241‐254.
Blanch M, Mosquera JL, Ansoleaga B, Ferrer I, Barrachina M. Altered mitochondrial DNA methylation pattern in Alzheimer disease–related pathology and in Parkinson disease. Am J Pathol. 2016;186(2):385‐397.
Stoccoro A, Siciliano G, Migliore L, Coppedè F. Decreased methylation of the mitochondrial D‐loop region in late‐onset Alzheimer's disease. J Alzheimers Dis. 2017;59(2):559‐564.
Vandecasteele G, Szabadkai G, Rizzuto R. Mitochondrial calcium homeostasis: mechanisms and molecules. IUBMB Life. 2001;52(3‐5):213‐219.
Ge M, Chen S, Huang Y, Chen W, He L, Zhang Y. Role of calcium homeostasis in Alzheimer's disease. Neuropsychiatr Dis Treat. 2022;18:487.
Garcia‐Casas P, Rossini M, Filadi R, Pizzo P. Mitochondrial Ca2+ signaling and Alzheimer's disease: too much or too little? Cell Calcium. 2023;113:102757.
Calvo‐Rodriguez M, Hou SS, Snyder AC, et al. Increased mitochondrial calcium levels associated with neuronal death in a mouse model of Alzheimer's disease. Nat Commun. 2020;11(1):2146.
Jadiya P, Kolmetzky DW, Tomar D, et al. Impaired mitochondrial calcium efflux contributes to disease progression in models of Alzheimer's disease. Nat Commun. 2019;10(1):3885.
Britti E, Ros J, Esteras N, Abramov AY. Tau inhibits mitochondrial calcium efflux and makes neurons vulnerable to calcium‐induced cell death. Cell Calcium. 2020;86:102150.
Shevtsova EF, Angelova PR, Stelmashchuk OA, et al. Pharmacological sequestration of mitochondrial calcium uptake protects against dementia and β‐amyloid neurotoxicity. Sci Rep. 2022;12(1):12766.
Kerr JS, Adriaanse BA, Greig NH, et al. Mitophagy and Alzheimer's disease: cellular and molecular mechanisms. Trends Neurosci. 2017;40(3):151‐166.
Uddin MS, Stachowiak A, Mamun AA, et al. Autophagy and Alzheimer's disease: from molecular mechanisms to therapeutic implications. Front Aging Neurosci. 2018;10:4.
Ihara Y, Morishima‐Kawashima M, Nixon R. The ubiquitin–proteasome system and the autophagic–lysosomal system in Alzheimer disease. Cold Spring Harb Perspect Med. 2012;2(8):a006361.
Fang EF, Hou Y, Palikaras K, et al. Mitophagy inhibits amyloid‐β and tau pathology and reverses cognitive deficits in models of Alzheimer's disease. Nat Neurosci. 2019;22(3):401‐412.
Ye X, Sun X, Starovoytov V, Cai Q. Parkin‐mediated mitophagy in mutant hAPP neurons and Alzheimer's disease patient brains. Hum Mol Genet. 2015;24(10):2938‐2951.
Mary A, Eysert F, Checler F, Chami M. Mitophagy in Alzheimer's disease: molecular defects and therapeutic approaches. Mol Psychiatry. 2023;28(1):202‐216.
Paillusson S, Stoica R, Gomez‐Suaga P, et al. There's something wrong with my MAM; the ER–mitochondria axis and neurodegenerative diseases. Trends Neurosci. 2016;39(3):146‐157.
Dentoni G, Castro‐Aldrete L, Naia L, Ankarcrona M. The potential of small molecules to modulate the mitochondria–endoplasmic reticulum interplay in Alzheimer's disease. Front Cell Dev Biol. 2022;10:920228.
Marchi S, Patergnani S, Pinton P. The endoplasmic reticulum–mitochondria connection: one touch, multiple functions. Biochim Biophys Acta (BBA)‐Bioenerg. 2014;1837(4):461‐469.
Magalhães Rebelo AP, Dal Bello F, Knedlik T, et al. Chemical modulation of mitochondria–endoplasmic reticulum contact sites. Cells. 2020;9(7):1637.
Schreiner B, Hedskog L, Wiehager B, Ankarcrona M. Amyloid‐β peptides are generated in mitochondria‐associated endoplasmic reticulum membranes. J Alzheimers Dis. 2015;43(2):369‐374.
Hedskog L, Pinho CM, Filadi R, et al. Modulation of the endoplasmic reticulum–mitochondria interface in Alzheimer's disease and related models. Proc Natl Acad Sci. 2013;110(19):7916‐7921.
Leal NS, Dentoni G, Schreiner B, et al. Amyloid Β‐peptide increases mitochondria‐endoplasmic reticulum contact altering mitochondrial function and autophagosome formation in Alzheimer's disease‐related models. Cells. 2020;9(12):2552.
Mahley RW. Apolipoprotein E4 targets mitochondria and the mitochondria‐associated membrane complex in neuropathology, including Alzheimer's disease. Curr Opin Neurobiol. 2023;79:102684.
Tambini MD, Pera M, Kanter E, et al. ApoE4 upregulates the activity of mitochondria‐associated ER membranes. EMBO Rep. 2016;17(1):27‐36.
Misrani A, Tabassum S, Yang L. Mitochondrial dysfunction and oxidative stress in Alzheimer's disease. Front Aging Neurosci. 2021;13. doi:10.3389/fnagi.2021.617588
Cassidy L, Fernandez F, Johnson JB, Naiker M, Owoola AG, Broszczak DA. Oxidative stress in alzheimer's disease: a review on emergent natural polyphenolic therapeutics. Complement Ther Med. 2020;49. doi:10.1016/J.CTIM.2019.102294
Llanos‐González E, Henares‐Chavarino ÁA, Pedrero‐Prieto CM, et al. Interplay between mitochondrial oxidative disorders and proteostasis in Alzheimer's disease. Front Neurosci. 2020;13:507129. doi:10.3389/FNINS.2019.01444/BIBTEX
Cheignon C, Tomas M, Bonnefont‐Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018;14:450‐464. doi:10.1016/J.REDOX.2017.10.014
Park L, Anrather J, Girouard H, Zhou P, Iadecola C. Nox2‐derived reactive oxygen species mediate neurovascular dysregulation in the aging mouse brain. J Cereb Blood Flow Metab. 2007;27(12):1908‐1918. doi:10.1038/SJ.JCBFM.9600491
Shabir O, Berwick J, Francis SE. Neurovascular dysfunction in vascular dementia, Alzheimer's and atherosclerosis. BMC Neurosci. 2018;19(1):62. doi:10.1186/s12868‐018‐0465‐5
Parodi‐Rullán R, Sone JY, Fossati S, Albensi B. Endothelial mitochondrial dysfunction in cerebral amyloid Angiopathy and Alzheimer's disease. J Alzheimers Dis. 2019;72(4):1019‐1039. doi:10.3233/JAD‐190357
Tarantini S, Fulop GA, Kiss T, et al. Demonstration of impaired neurovascular coupling responses in TG2576 mouse model of Alzheimer's disease using functional laser speckle contrast imaging. Geroscience. 2017;39(4):465‐473. doi:10.1007/S11357‐017‐9980‐Z
Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci. 2017;18(7):419‐434. doi:10.1038/NRN.2017.48
Kisler K, Nelson AR, Rege SV, et al. Pericyte degeneration leads to neurovascular uncoupling and limits oxygen supply to brain. Nat Neurosci. 2017;20(3):406‐416. doi:10.1038/NN.4489
Montagne A, Nikolakopoulou AM, Zhao Z, et al. Pericyte degeneration causes white matter dysfunction in the mouse central nervous system. Nat Med. 2018;24(3):326‐337. doi:10.1038/NM.4482
Maioli S, Leander K, Nilsson P, Nalvarte I. Estrogen receptors and the aging brain. Essays Biochem. 2021;65(6):913‐925. doi:10.1042/EBC20200162
Chen P, Li B, Ou‐Yang L. Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne). 2022;13:839005. doi:10.3389/FENDO.2022.839005/BIBTEX
Hwang WJ, Lee TY, Kim NS, Kwon JS. The role of estrogen receptors and their signaling across psychiatric disorders. Int J Mol Sci. 2020;22(1):373. doi:10.3390/IJMS22010373
Mehra RD, Sharma K, Nyakas C, Vij U. Estrogen receptor α and β immunoreactive neurons in normal adult and aged female rat hippocampus: a qualitative and quantitative study. Brain Res. 2005;1056(1):22‐35. doi:10.1016/J.BRAINRES.2005.06.073
Waters EM, Yildirim M, Janssen WGM, et al. Estrogen and aging affect the synaptic distribution of estrogen receptor beta‐immunoreactivity in the CA1 region of female rat hippocampus. Brain Res. 2011;1379:86‐97. doi:10.1016/J.BRAINRES.2010.09.069
Adams MM, Fink SE, Shah RA, et al. Estrogen and aging affect the subcellular distribution of estrogen receptor‐α in the hippocampus of female rats. J Neurosci. 2002;22(9):3608‐3614. doi:10.1523/JNEUROSCI.22‐09‐03608.2002
Hu XY, Qin S, Lu YP, Ravid R, Swaab DF, Zhou JN. Decreased estrogen receptor‐α expression in hippocampal neurons in relation to hyperphosphorylated tau in Alzheimer patients. Acta Neuropathol. 2003;106(3):213‐220. doi:10.1007/S00401‐003‐0720‐3
Hestiantoro A, Swaab DF. Changes in estrogen receptor‐α and ‐β in the infundibular nucleus of the human hypothalamus are related to the occurrence of Alzheimer's disease neuropathology. J Clin Endocrinol Metab. 2004;89(4):1912‐1925. doi:10.1210/JC.2003‐030862
Ishunina TA, Swaab DF. Increased neuronal metabolic activity and estrogen receptors in the vertical limb of the diagonal band of broca in Alzheimer's disease: relation to sex and aging. Exp Neurol. 2003;183(1):159‐172. doi:10.1016/S0014‐4886(03)00138‐9
Ishunina TA, Kamphorst W, Swaab DF. Changes in metabolic activity and estrogen receptors in the human medial mamillary nucleus: relation to sex, aging and Alzheimer's disease. Neurobiol Aging. 2003;24(6):817‐828. doi:10.1016/S0197‐4580(03)00009‐5
Ishunina TA, Swaab DF. Increased expression of estrogen receptor α and β in the nucleus basalis of Meynert in Alzheimer's disease. Neurobiol Aging. 2001;22(3):417‐426. doi:10.1016/S0197‐4580(00)00255‐4
Tian Z, Fan J, Zhao Y, Bi S, Si LH, Liu Q. Estrogen receptor beta treats Alzheimer's disease. Neural Regen Res. 2013;8(5):420‐426. doi:10.3969/J.ISSN.1673‐5374.2013.05.005
Long J, He P, Shen Y, Li R. New evidence of mitochondria dysfunction in the female Alzheimer's disease brain: deficiency of estrogen receptor‐β. J Alzheimers Dis. 2012;30(3):545‐558. doi:10.3233/JAD‐2012‐120283
Chen JQ, Delannoy M, Cooke C, Yager JD. Mitochondrial localization of ERα and ERβ in human MCF7 cells. Am J Physiol Endocrinol Metab. 2004;286(6):1011‐1022. doi:10.1152/AJPENDO.00508.2003/ASSET/IMAGES/LARGE/ZH10060416910006.JPEG
Razmara A, Sunday L, Stirone C, et al. Mitochondrial effects of estrogen are mediated by estrogen receptor α in brain endothelial cells. J Pharmacol Exp Ther. 2008;325(3):782‐790. doi:10.1124/JPET.107.134072
Milner TA, Ayoola K, Drake CT, et al. Ultrastructural localization of estrogen receptor β immunoreactivity in the rat hippocampal formation. J Comp Neurol. 2005;491(2):81‐95. doi:10.1002/CNE.20724
Irwin RW, Yao J, To J, Hamilton RT, Cadenas E, Brinton RD. Selective oestrogen receptor modulators differentially potentiate brain mitochondrial function. J Neuroendocrinol. 2012;24(1):236‐248. doi:10.1111/J.1365‐2826.2011.02251.X
Klinge CM. Estrogens regulate life and death in mitochondria. J Bioenerg Biomembr. 2017;49(4):307‐324. doi:10.1007/S10863‐017‐9704‐1
Oo PS, Yamaguchi Y, Sawaguchi A, et al. Estrogen regulates mitochondrial morphology through phosphorylation of dynamin‐related protein 1 in MCF7 human breast cancer cells. Acta Histochem Cytochem. 2018;51(1):21‐31. doi:10.1267/AHC.17034
Mattingly KA, Ivanova MM, Riggs KA, Wickramasinghe NS, Barch MJ, Klinge CM. Estradiol stimulates transcription of nuclear respiratory Factor‐1 and increases mitochondrial biogenesis. Mol Endocrinol. 2008;22(3):609‐622. doi:10.1210/ME.2007‐0029
Nilsen J, Irwin RW, Gallaher TK, Brinton RD. Estradiol in vivo regulation of brain mitochondrial proteome. J Neurosci. 2007;27(51):14069‐14077. doi:10.1523/JNEUROSCI.4391‐07.2007
Yao J, Irwin R, Chen S, Hamilton R, Cadenas E, Brinton RD. Ovarian hormone loss induces bioenergetic deficits and mitochondrial β‐amyloid. Neurobiol Aging. 2012;33(8):1507‐1521. doi:10.1016/J.NEUROBIOLAGING.2011.03.001
Oddo S, Caccamo A, Shepherd JD, et al. Triple‐transgenic model of Alzheimer's disease with plaques and tangles: intracellular Aβ and synaptic dysfunction. Neuron. 2003;39(3):409‐421. doi:10.1016/S0896‐6273(03)00434‐3
Irwin RW, Yao J, Hamilton RT, Cadenas E, Brinton RD, Nilsen J. Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. Endocrinology. 2008;149(6):3167‐3175. doi:10.1210/EN.2007‐1227
Irwin RW, Yao J, Ahmed SS, Hamilton RT, Cadenas E, Brinton RD. Medroxyprogesterone acetate antagonizes estrogen up‐regulation of brain mitochondrial function. Endocrinology. 2011;152(2):556‐567. doi:10.1210/EN.2010‐1061
Bergersen LH, Gjedde A. Is lactate a volume transmitter of metabolic states of the brain? Front Neuroenergetics. 2012;4(MAR):22317. doi:10.3389/FNENE.2012.00005/BIBTEX
Radde BN, Ivanova MM, Mai HX, et al. Nuclear respiratory factor‐1 and bioenergetics in tamoxifen‐resistant breast cancer cells. Exp Cell Res. 2016;347(1):222‐231. doi:10.1016/J.YEXCR.2016.08.006
Olsen BB, Gjedde A, Vilstrup MH, et al. Linked hexokinase and glucose‐6‐phosphatase activities reflect grade of ovarian malignancy. Mol Imaging Biol. 2019;21(2):375‐381. doi:10.1007/s11307‐018‐1247‐2
Imbert‐Fernandez Y, Clem BF, O'Neal J, et al. Estradiol stimulates glucose metabolism via 6‐phosphofructo‐2‐kinase (PFKFB3). J Biol Chem. 2014;289(13):9440‐9448. doi:10.1074/JBC.M113.529990
Kostanyan A, Nazaryan K. Rat brain glycolysis regulation by estradiol‐17β. Biochim Biophys Acta (BBA) ‐ Molecular Cell Res. 1992;1133(3):301‐306. doi:10.1016/0167‐4889(92)90051‐C
Cheng CM, Cohen M, Wang J, Bondy CA. Estrogen augments glucose transporter and IGF1 expression in primate cerebral cortex. FASEB j. 2001;15(6):907‐915. doi:10.1096/FSB2FJ000398COM
Luo M, Zeng Q, Jiang K, et al. Estrogen deficiency exacerbates learning and memory deficits associated with glucose metabolism disorder in APP/PS1 double transgenic female mice. Genes Dis. 2022;9(5):1315‐1331. doi:10.1016/J.GENDIS.2021.01.007
Brinton RD. Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. Adv Drug Deliv Rev. 2008;60(13‐14):1504‐1511. doi:10.1016/J.ADDR.2008.06.003
Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase‐II. Cell Death Differ. 2007;15(3):521, ‐529. doi:10.1038/sj.cdd.4402285
Mendez P, Wandosell F, Garcia‐Segura LM. Cross‐talk between estrogen receptors and insulin‐like growth factor‐I receptor in the brain: cellular and molecular mechanisms. Front Neuroendocrinol. 2006;27(4):391‐403. doi:10.1016/J.YFRNE.2006.09.001
Arjunan A, Sah DK, Woo M, Song J. Identification of the molecular mechanism of insulin‐like growth factor‐1 (IGF‐1): a promising therapeutic target for neurodegenerative diseases associated with metabolic syndrome. Cell Biosci. 2023;13(1):1‐18. doi:10.1186/S13578‐023‐00966‐Z
Cheng CM, Reinhardt RR, Lee WH, Joncas G, Patel SC, Bondy CA. Insulin‐like growth factor 1 regulates developing brain glucose metabolism. Proc Natl Acad Sci U S A. 2000;97(18):10236‐10241. doi:10.1073/PNAS.170008497/ASSET/28091DAD‐1CFF‐4666‐A400‐EDECA938B1B4/ASSETS/GRAPHIC/PQ1700084004.JPEG
Sędzikowska A, Szablewski L. Insulin and insulin resistance in Alzheimer's disease. Int J Mol Sci. 2021;22(18):9987. doi:10.3390/IJMS22189987
Gupte AA, Pownall HJ, Hamilton DJ. Estrogen: an emerging regulator of insulin action and mitochondrial function. J Diabetes Res. 2015;2015:916585. doi:10.1155/2015/916585
Yan H, Yang W, Zhou F, et al. Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor Foxo1. Diabetes. 2019;68(2):291‐304. doi:10.2337/DB18‐0638
De Paoli M, Zakharia A, Werstuck GH. The role of estrogen in insulin resistance: a review of clinical and preclinical data. Am J Pathol. 2021;191(9):1490‐1498. doi:10.1016/J.AJPATH.2021.05.011
Giuffrida ML, Tomasello F, Caraci F, Chiechio S, Nicoletti F, Copani A. Beta‐amyloid monomer and insulin/IGF‐1 signaling in Alzheimer's disease. Mol Neurobiol. 2012;46(3):605‐613. doi:10.1007/S12035‐012‐8313‐6/FIGURES/1
Carro E, Trejo JL, Gomez‐Isla T, LeRoith D, Torres‐Aleman I. Serum insulin‐like growth factor I regulates brain amyloid‐β levels. Nat Med. 2002;8(12):1390‐1397. doi:10.1038/nm1202‐793
Bian C, Bai B, Gao Q, Li S, Zhao Y. 17β‐estradiol regulates glucose metabolism and insulin secretion in rat islet β cells through GPER and Akt/mTOR/GLUT2 pathway. Front Endocrinol (Lausanne). 2019;10:455753. doi:10.3389/FENDO.2019.00531/BIBTEX
Yao J, Hamilton RT, Cadenas E, Brinton RD. Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. Biochim Biophys Acta (BBA) ‐ Gen Subj. 2010;1800(10):1121‐1126. doi:10.1016/J.BBAGEN.2010.06.002
Sastre‐Serra J, Nadal‐Serrano M, Pons DG, Roca P, Oliver J. The over‐expression of ERbeta modifies estradiol effects on mitochondrial dynamics in breast cancer cell line. Int J Biochem Cell Biol. 2013;45(7):1509‐1515. doi:10.1016/J.BIOCEL.2013.04.007
Sarkar S, Jun S, Simpkins JW. Estrogen amelioration of Aβ‐induced defects in mitochondria is mediated by mitochondrial signaling pathway involving ERβ, AKAP and Drp1. Brain Res. 2015;1616:101‐111. doi:10.1016/J.BRAINRES.2015.04.059
Ribas V, Drew BG, Zhou Z, et al. Skeletal muscle action of estrogen receptor a is critical for the maintenance of mitochondrial function and metabolic homeostasis in females. Sci Transl Med. 2016;8(334). doi:10.1126/SCITRANSLMED.AAD3815/SUPPL_FILE/8‐334RA54_SM.PDF
Torres MJ, Ryan TE, Te LC, Zeczycki TN, Neufer PD. Impact of 17β‐estradiol on complex I kinetics and H2O2 production in liver and skeletal muscle mitochondria. J Biol Chem. 2018;293(43):16889‐16898. doi:10.1074/JBC.RA118.005148
Wegner MS, Gruber L, Schömel N, et al. GPER1 influences cellular homeostasis and cytostatic drug resistance via influencing long chain ceramide synthesis in breast cancer cells. Int J Biochem Cell Biol. 2019;112:95‐106. doi:10.1016/J.BIOCEL.2019.05.002
Wang J, Yu R, Han QQ, et al. G‐1 exhibit antidepressant effect, increase of hippocampal ERs expression and improve hippocampal redox status in aged female rats. Behav Brain Res. 2019;359:845‐852. doi:10.1016/J.BBR.2018.07.017
Tran QK. Reciprocality between estrogen biology and calcium signaling in the cardiovascular system. Front Endocrinol (Lausanne). 2020;11:568203. doi:10.3389/FENDO.2020.568203/BIBTEX
Castoria G, Migliaccio A, Nola E, Auricchio F. In vitro interaction of estradiol receptor with Ca2+‐calmodulin. Mol Endocrinol. 1988;2(2):167‐174. doi:10.1210/MEND‐2‐2‐167
García Pedrero JM, Del Rio B, Martínez‐Campa C, Muramatsu M, Lazo PS, Ramos S. Calmodulin is a selective modulator of estrogen receptors. Mol Endocrinol. 2002;16(5):947‐960. doi:10.1210/MEND.16.5.0830
Tran QK, VerMeer M. Biosensor‐based approach identifies four distinct calmodulin‐binding domains in the G protein‐coupled estrogen receptor 1. PLoS ONE. 2014;9(2):e89669. doi:10.1371/JOURNAL.PONE.0089669
Tran QK, Firkins R, Giles J, et al. Estrogen enhances linkage in the vascular endothelial calmodulin network via a feedforward mechanism at the G protein‐coupled estrogen receptor 1. J Biol Chem. 2016;291(20):10805‐10823. doi:10.1074/JBC.M115.697334
Sarkar SN, Huang RQ, Logan SM, Kun DY, Dillon GH, Simpkins JW. Estrogens directly potentiate neuronal L‐type Ca2+ channels. Proc Natl Acad Sci U S A. 2008;105(39):15148‐15153. doi:10.1073/PNAS.0802379105/SUPPL_FILE/0802379105SI.PDF
Wu TW, Chen S, Brinton RD. Membrane estrogen receptors mediate calcium signaling and MAP kinase activation in individual hippocampal neurons. Brain Res. 2011;1379:34‐43. doi:10.1016/J.BRAINRES.2011.01.034
Chaban VV, Lakhter AJ, Micevych P. A membrane estrogen receptor mediates intracellular calcium release in astrocytes. Endocrinology. 2004;145(8):3788‐3795. doi:10.1210/EN.2004‐0149
Lobatón CD, Vay L, Hernández‐SanMiguel E, et al. Modulation of mitochondrial Ca2+ uptake by estrogen receptor agonists and antagonists. Br J Pharmacol. 2005;145(7):862‐871. doi:10.1038/SJ.BJP.0706265
Horvat A, Petrović S, Nedeljkovic N, Martinović J, Nikezić G. Estradiol affect Na‐dependent Ca2+ efflux from synaptosomal mitochondria. Gen Physiol Biophys. 2000;19(1):59‐71.
Petrović S, Demajo M, Horvat A. Estradiol affects calcium transport across mitochondrial membrane in different brain regions. Ann N Y Acad Sci. 2005;1048:341‐343. doi:10.1196/annals.1342.032
Nilsen J, Brinton RD. Mechanism of estrogen‐mediated neuroprotection: regulation of mitochondrial calcium and Bcl‐2 expression. Proc Natl Acad Sci U S A. 2003;100(5):2842‐2847. doi:10.1073/PNAS.0438041100/ASSET/9D85E821‐162A‐41D3‐8D5E‐784B414FDF6D/ASSETS/GRAPHIC/PQ0438041005.JPEG
Brewer GJ, Reichensperger JD, Brinton RD. Prevention of age‐related dysregulation of calcium dynamics by estrogen in neurons. Neurobiol Aging. 2006;27(2):306‐317. doi:10.1016/J.NEUROBIOLAGING.2005.01.019
Burstein SR, Kim HJ, Fels JA, et al. Estrogen receptor beta modulates permeability transition in brain mitochondria. Biochim Biophys Acta (BBA) ‐ Bioenerg. 2018;1859(6):423‐433. doi:10.1016/J.BBABIO.2018.03.006
De La Monte SM, Lu BX, Sohn YK, et al. Aberrant expression of nitric oxide synthase III in Alzheimer's disease: relevance to cerebral vasculopathy and neurodegeneration. Neurobiol Aging. 2000;21(2):309‐319. doi:10.1016/S0197‐4580(99)00108‐6
Hariharan A, Jing Y, Collie ND, Zhang H, Liu P. Altered neurovascular coupling and brain arginine metabolism in endothelial nitric oxide synthase deficient mice. Nitr Oxide. 2019;87:60‐72. doi:10.1016/J.NIOX.2019.03.006
Pang Y, Thomas P. Additive effects of low concentrations of estradiol‐17β and progesterone on nitric oxide production by human vascular endothelial cells through shared signaling pathways. J Steroid Biochem Mol Biol. 2017;165:258‐267. doi:10.1016/J.JSBMB.2016.06.014
Gaudet HM, Cheng SB, Christensen EM, Filardo EJ. The G‐protein coupled estrogen receptor, GPER: the inside and inside‐out story. Mol Cell Endocrinol. 2015;418:207‐219. doi:10.1016/J.MCE.2015.07.016
Wyckoff MH, Chambliss KL, Mineo C, et al. Plasma membrane estrogen receptors are coupled to endothelial nitric‐oxide synthase through Gαi. J Biol Chem. 2001;276(29):27071‐27076. doi:10.1074/jbc.M100312200
Haynes MP, Sinha D, Russell KS, et al. Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3‐kinase–Akt pathway in human endothelial cells. Circ Res. 2000;87(8):677‐682. doi:10.1161/01.RES.87.8.677
Lourenço CF, Laranjinha J. Nitric oxide pathways in neurovascular coupling under Normal and stress conditions in the brain: strategies to rescue aberrant coupling and improve cerebral blood flow. Front Physiol. 2021;12:729201. doi:10.3389/FPHYS.2021.729201/BIBTEX
Razmara A, Duckles SP, Krause DN, Procaccio V. Estrogen suppresses brain mitochondrial oxidative stress in female and male rats. Brain Res. 2007;1176(1):71‐81. doi:10.1016/J.BRAINRES.2007.08.036